[1]
|
Fuchs, V.R. and Milstein, A. (2011) The $640 Billion Question—Why Does Cost-Effective Care Diffuse So Slowly? The New England Journal of Medicine, 364, 1985-1987. https://doi.org/10.1056/NEJMp1104675
|
[2]
|
Xu, J., Murphy, S.L., Kochanek, M.A. and Arias, E. (2016) Mortality in the United States, 2015. NCHS Data Brief, No. 267.
https://www.cdc.gov/nchs/products/databriefs/db267.htm
|
[3]
|
Benjamin, E.J., Virani, S.S., Callaway, C.W., Chamberlain, A.M., Chang, A.R., Cheng, S. and the Writing Group Members (2018) AHA Statistical Update: Heart Disease and Stroke Statistics—2018 Update: A Report from the American Heart Association. Circulation, 137, e67-e492.
https://doi.org/10.1161/CIR.0000000000000573
|
[4]
|
American Heart Association CVD Burden Report (2017) Cardiovascular Disease: A Costly Burden for America-Projections through 2035.
https://www.heart.org/-/media/Files/Get-Involved/Advocacy/Burden-Report-Consumer-Report.pdf
|
[5]
|
Gao, W.-Q., Feng, Q.-Z., Li, Y.-F., Li, Y.-X., Huang, Y., Chen, Y.-M., et al. (2014) Systematic Study of the Effects of Lowering Low-Density Lipoprotein-Cholesterol on Regression of Coronary Atherosclerotic Plaques Using Intravascular Ultrasound. BMC Cardiovascular Disorders, 14, 60-78. https://doi.org/10.1186/1471-2261-14-60
|
[6]
|
Nissen, S.E., Nicholls, S.J., Sipahi, I., Libby, P., Raichlen, J.S., Ballantyne, C.M., et al. for the ASTEROID Investigators. (2006) Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis—The ASTEROID Trial. JAMA, 295, 1556-1565. https://doi.org/10.1001/jama.295.13.jpc60002
|
[7]
|
Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, J., Barnes, E.H., et al. (2012) The Effects of Lowering LDL Cholesterol with Statin Therapy in People at Low Risk of Vascular Disease: Meta-Analysis of Individual Data from 27 Randomised Trials. The Lancet, 380, 581-590.
https://doi.org/10.1016/S0140-6736(12)60367-5
|
[8]
|
[A4] Schade, D.S. and Eaton, R.P. (2019) A Simplified Approach to Reducing Cardiovascular Risk. Journal of Clinical Endocrinology & Metabolism, 104, 6033-6039.
https://doi.org/10.1210/jc.2018-02509
|
[9]
|
Eaton, R.P., Burge, M.R., Comerci, G., Cavanaugh, B., Ramo, B. and Schade, D.S. (2016) Abnormal Coronary Artery Calcium Scans in Asymptomatic Patients. The American Journal of Medicine, 130, 394-397.
https://doi.org/10.1016/j.amjmed.2016.10.006
|
[10]
|
Arnett, D.K., Blumenthal, R.S., Albert, M.A., Michos, E.D., Buroker, A.B., Miedema, M.D., et al. (2019) 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140, e596-e646.
https://doi.org/10.1016/j.jacc.2019.03.010
|
[11]
|
Khanji, M.Y., Bicalho, V.S., van Waardhuizen, C.N., Ferket, B.S., Petersen, S.E. and Myriam Hunink, M. (2016) Cardiovascular Risk Assessment: A Systematic Review of Guidelines. Annals of Internal Medicine, 165, 713-722.
https://doi.org/10.7326/M16-1110
|
[12]
|
Rana, J.S., Tabada, G.H., Soloman, M.D., Lo, J.C., Jaffe, M.G., Sung, S.H., et al. (2016) Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Real-World Population. Journal of the American College of Cardiology, 67, 2118-2130. https://doi.org/10.1016/j.jacc.2016.02.055
|
[13]
|
DeFilippis, A.P., Young, R., McEvoy, J.W., Michos, E.D., Sandfort, V., Kronmal, R.A., et al. (2017) Risk Score Overestimation: The Impact of Individual Cardiovascular Risk Factors and Preventive Therapies on the Performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease Risk Score in a Modern Multi-Ethnic Cohort. European Heart Journal, 38, 598-608. https://doi.org/10.1093/eurheartj/ehw301
|
[14]
|
Michos, E.D., Nasir, K., Braunstein, J.B., Rumberger, J.A., Budoff, M.J., Post, W.S., et al. (2006) Framingham Risk Equation Underestimates Subclinical Atherosclerosis Risk in Asymptomatic Women. Atherosclerosis, 184, 201-206.
https://doi.org/10.1016/j.atherosclerosis.2005.04.004
|
[15]
|
Tuzcu, E.M., Kapadia, S.R., Tutar, E., Ziada, K.M., Hobbs, R.E., McCarthy, P.M., et al. (2001) High Prevalence of Coronary Atherosclerosis in Asymptomatic Teenagers and Young Adults. Circulation, 103, 2705-2710.
https://doi.org/10.1161/01.CIR.103.22.2705
|
[16]
|
Stary, H.C. (1989) Evolution and Progression of Atherosclerotic Lesions in Coronary Arteries of Children and Young Adults. Arteriosclerosis, I9, I19-I32.
|
[17]
|
Schade, D.S., Murphy, S., Exil, V. and Eaton, P. (2018) A Pediatric Opportunity in Adolescents to Prevent Adult Heart Attacks. World Journal of Cardiovascular Diseases, 8, 85-101. https://doi.org/10.4236/wjcd.2018.82009
|
[18]
|
Schade, D.S., Obenshain, S.S., Ramo, B. and Eaton, R.P. (2019) A Feasible, Simple, Cost-Saving Program to End Cardiovascular Disease in the United States. American Journal of Medicine, 132, 1365-1367. https://doi.org/10.1016/j.amjmed.2019.03.043
|
[19]
|
Detrano, R., Guerci, A.D., Carr, J., Bild, D.E., Burke, G., Folsom, A.R., et al. (2008) Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups. The New England Journal of Medicine, 358, 1336-1345.
https://doi.org/10.1056/NEJMoa072100
|
[20]
|
Schade, D.S., Arora, S. and Eaton, R.P. (2020) Should Routine Screening for Coronary Artery Disease Be Recommended? A Comparison with Routine Screening for Colon Cancer. The American Journal of Medicine, 133, 155-157.
https://doi.org/10.1016/j.amjmed.2019.06.032
|
[21]
|
Morris, Z.S., Wooding, S. and Grant, J. (2011) The Answer is 17 Years, What Is the Question: Understanding Time Lags in Translational Research. Journal of the Royal Society of Medicine, 104, 510-520. https://doi.org/10.1258/jrsm.2011.110180
|
[22]
|
Hecht, H., Blaha, M.J., Berman, D.S., Nasir, K., Budoff, M., Leipsic, J., et al. (2017) Clinical Indications for Coronary Artery Calcium Scoring in Asymptomatic Patients: Expert Consensus Statement from the Society of Cardiovascular Computed Tomography. Journal of Cardiovascular Computed Tomography, 11, 157-168.
https://doi.org/10.1016/j.jcct.2017.02.010
|
[23]
|
Rumberger, J.A., Schwartz, R.S., Simons, B., Sheedy, P.F., Edwards, W.D. and Fitzpatrick, L.A. (1994) Relation of Coronary Calcium Determined by Electron Beam Computed Tomography and Lumen Narrowing Determined by Autopsy. The American Journal of Cardiology, 74, 1169-1173.
https://doi.org/10.1016/0002-9149(94)90176-7
|
[24]
|
Greenland, P., Blaha, M., Budoff, M., Erbel, R. and Watson, K. (2018) Coronary Calcium Score and Cardiovascular Risk. Journal of the American College of Cardiology, 72, 434-447. https://doi.org/10.1016/j.jacc.2018.05.027
|
[25]
|
Shaw, L., Giambrone, A.E., Blaha, M.J., Knapper, J.T., Berman, D.S., Bellam, N., et al. (2015) Long-Term Prognosis after Coronary Artery Calcification Testing: A Cohort Study. Annals of Internal Medicine, 163, 14-21.
https://doi.org/10.7326/M14-0612
|
[26]
|
McClelland, R.L., Jorgensen, N.W., Budoff, M., Blaha, M.J., Post, W.S., Kronmal, R.A., et al. (2015) 10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). Journal of the American College of Cardiology, 66, 1643-1653. https://doi.org/10.1016/j.jacc.2015.08.035
|
[27]
|
Mamudu, H.M., Paul, T.K., Veeranki, S.P. and Budoff, M. (2014) The Effects of Coronary Artery Calcium Screening on Behavioral Modification, Risk Perception, and Medication Adherence Among Asymptomatic Adults: A Systematic Review. Atherosclerosis, 236, 338-350. https://doi.org/10.1016/j.atherosclerosis.2014.07.022
|
[28]
|
Hecht, H.S. (2015) Coronary Artery Calcium Scanning: Past, Present, and Future. JACC: Cardiovascular Imaging, 8, 579-596.
https://doi.org/10.1016/j.jcmg.2015.02.006
|
[29]
|
Taylor, A.J., Bindeman, J., Feuerstein, I., Cao, F., Brazaitis, M. and O’Malley, P.G. (2005) Coronary Calcium Independently Predicts Incident Premature Coronary Heart Disease Over Measured Cardiovascular Risk Factors: Mean Three-Year Outcomes in the Prospective Army Coronary Calcium (PACC) Project. Journal of the American College of Cardiology, 46, 807-814.
https://doi.org/10.1016/j.jacc.2005.05.049
|
[30]
|
Bild, D.E., Bluemke, D.A., Burke, G.L., Detrano, R., Diez Roux, A.V., Folsom, A.R., et al. (2005) Ethnic Differences in Coronary Calcification the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation, 111, 1313-1320.
https://doi.org/10.1161/01.CIR.0000157730.94423.4B
|
[31]
|
Cheng, V.Y., Lepor, N.E., Madyoon, H., Eshaghian, S., Naraghi, A.L. and Shah, P.K. (2007) Presence and Severity of Noncalcified Coronary Plaque on 64-Slice Computed Tomographic Coronary Angiography in Patients with Zero and Low Coronary Artery Calcium. The American Journal of Cardiology, 99, 1183-1186.
https://doi.org/10.1016/j.amjcard.2006.12.026
|
[32]
|
Raggi, P., Cooil, B., Ratti, C., Callister, T.Q. and Budoff, M. (2005) Progression of Coronary Artery Calcium and Occurrence of Myocardial Infarction in Patients with and without Diabetes Mellitus. Hypertension, 46, 238-243.
https://doi.org/10.1161/01.HYP.0000164575.16609.02
|
[33]
|
Blaha, M.J., Blumenthal, R.S., Budoff, M.J. and Nasir, K. (2011) Understanding the Utility of Zero Coronary Calcium as a Prognostic Test: A Bayesian Approach. Circulation: Cardiovascular Quality and Outcomes, 4, 253-256.
https://doi.org/10.1161/CIRCOUTCOMES.110.958496
|
[34]
|
Burge, M.R., Eaton, R.P., Comerci, G., Cavanaugh, B., Ramo, B. and Schade D.S. (2017) Management of Asymptomatic Patients with Positive Coronary Artery Calcium Scans. Journal of the Endocrine Society, 1, 588-599.
https://doi.org/10.1210/js.2016-1080
|
[35]
|
Cholesterol Treatment Trialists’ (CTT) Collaboration (2010) Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-Analysis of Data from 170,000 Participants in 26 Randomised Trials. The Lancet, 376, 1670-1681.
https://doi.org/10.1016/S0140-6736(10)61350-5
|
[36]
|
Jarcho, J.A. and Keaney, J.F. (2015) Proof that Lower Is Better-LDL Cholesterol and IMPROVE-IT. The New England Journal of Medicine, 372, 2448-2450.
https://doi.org/10.1056/NEJMe1507041
|
[37]
|
Brown, M.S. and Goldstein, J.L (2006) Lowering LDL—Not Only How Low, but How Long? Science, 311, 1721-1723. https://doi.org/10.1126/science.1125884
|
[38]
|
Keraliya, A. and Blankstein, R. (2017) Regression of Coronary Atherosclerosis with Medical Therapy. The New England Journal of Medicine, 376, 1370.
https://doi.org/10.1056/NEJMicm1609054
|
[39]
|
Lazar, L.D., Pletcher, M.J., Coxson, P.G., Bibbins-Domingo, K. and Goldman, L. (2011) Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era. Circulation, 124, 146-153.
https://doi.org/10.1161/CIRCULATIONAHA.110.986349
|
[40]
|
Kashani, A., Phillips, C.O., Foody, J.M., Wang, Y., Mangalmurti, S., Ko, D.T., et al. (2006) Risks Associated with Statin Therapy: A Systematic Overview of Randomized Clinical Trials. Circulation, 114, 2788-2797.
https://doi.org/10.1161/CIRCULATIONAHA.106.624890
|
[41]
|
Nissen, S.E. (2017) Statin Denial: An Internet-Driven Cult with Deadly Consequences. Annals of Internal Medicine, 167, 281-282.
https://doi.org/10.7326/M17-1566
|
[42]
|
Schade, D.S., Gonzales, K., Kaminsky, N., Adolphe, A., Shey, L. and Eaton, R.P. (2022) Resolving the Egg and Cholesterol Intake Controversy: New Clinical Insights into Cholesterol Regulation by the Liver and Intestine. Endocrine Practice, 28, 102-109.
https://doi.org/10.1016/j.eprac.2021.09.004
|
[43]
|
Guo, S., Li, L. and Yin, H. (2018) Cholesterol Homeostasis and Liver X Receptor (LXR) in Atherosclerosis. Cardiovascular & Hematological Disorders Drug Targets, 18, 27-33. https://doi.org/10.2174/1871529X18666180302113713
|
[44]
|
Repa, J.J. and Mangelsdorf, D.J. (2002) The Live X Receptor Gene Team: Potential New Players in Atherosclerosis. Nature Medicine, 8, 1243-1248.
https://doi.org/10.1038/nm1102-1243
|
[45]
|
Scott, J. (2007) The Liver X Receptor and Atherosclerosis. The New England Journal of Medicine, 357, 2195-2197. https://doi.org/10.1056/NEJMcibr075951
|
[46]
|
Tremblay, A.J., Lamarche, B., Lemelin, V., Hoos, L., Benjannet, S., Seidah, N.G., et al. (2011) Atorvastatin Increases Intestinal Expression of NPC1L1 in Hyperlipidemic Men. Journal of Lipid Research, 52, 558-565.
https://doi.org/10.1194/jlr.M011080
|
[47]
|
Maron, D.J., Hartigan, P.M., Neff, D.R., Weintraub, W.S. and Boden, W.E. (2013) Impact of Adding Ezetimibe to Statin to Achieve Low-Density Lipoprotein Cholesterol Goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] Trial). American Journal of Cardiology, 111, 1557-1562. https://doi.org/10.1016/j.amjcard.2013.02.005
|
[48]
|
Kosoglou, T., Statkevich, P., Johnson-Levonas, A.M., Paolini, J.F., Bergman, A.J. and Alton, K.B. (2005) Ezetimibe: A Review of Its Metabolism, Pharmacokinetics and Drug Interactions. Clinical Pharmacokinetics, 44, 467-494.
https://doi.org/10.2165/00003088-200544050-00002
|
[49]
|
Mirzaee, S., Thein, P.M., Nogic, J., Nerlekar, N., Nasis, A. and Brown, A.J. (2018) The Effect of Combined Ezetimibe and Statin Therapy versus Statin Therapy Alone on Coronary Plaque Volume Assessed by Intravascular Ultrasound: A Systematic Review and Meta-Analysis. Journal of Clinical Lipidology, 12, 1133-1140.
https://doi.org/10.1016/j.jacl.2018.06.001
|
[50]
|
Ballantyne, C.M., Houri, J., Notarbartolo, A., Melani, L., Lipka, L.J., Suresh, R., et al. (2003) Effect of Ezetimibe Coadministered with Atorvastatin in 628 Patients with Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial. Circulation, 107, 2409-2415. https://doi.org/10.1161/01.CIR.0000068312.21969.C8
|
[51]
|
Hecht, H.S. and Narula, J. (2012) Coronary Artery Calcium Scanning in Asymptomatic Patients with Diabetes Mellitus: A Paradigm Shift. Journal of Diabetes, 4, 342-350. https://doi.org/10.1111/j.1753-0407.2012.00212.x
|
[52]
|
Min, J.K., Lin, F.Y., Gidseg, D.S., Weinsaft, J.W., Berman, D.S., Shaw, L.J., et al. (2010) Determinants of Coronary Calcium Conversion among Patients with a Normal Coronary Calcium Scan. Journal of the American College of Cardiology, 55, 1110-1117. https://doi.org/10.1016/j.jacc.2009.08.088
|
[53]
|
Sarwar, A., Shaw, L.J., Shapiro, M.D., Blankstein, R., Hoffman, U., Cury, R.C., et al. (2009) Diagnostic and Prognostic Value of Absence of Coronary Artery Calcification. JACC: Cardiovascular Imaging, 2, 675-688.
https://doi.org/10.1016/j.jcmg.2008.12.031
|
[54]
|
Budoff, M.J., McClelland, R.L., Nasir, K., Greenland, P., Kronmal, R.A., Kondos, G.T., et al. (2009) Cardiovascular Events with Absent or Minimal Coronary Calcification: The Multi-Ethnic Study of Atherosclerosis (MESA). American Heart Journal, 158, 554-561. https://doi.org/10.1016/j.ahj.2009.08.007
|
[55]
|
Greenland, P. (2015) When Nothing Is Really Something: New Evidence of the Importance of Zero Coronary Calcium. JACC: Cardiovascular Imaging, 8, 910-912.
https://doi.org/10.1016/j.jcmg.2015.02.028
|
[56]
|
Baigent, C., Keech, A., Kearney, P.M., Blackwell, L., Buck, G., Pollicino, C., et al. (2005) Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90,056 Participants in 14 Randomised Trials of Statins. The Lancet, 366, 1267-1278. https://doi.org/10.1016/S0140-6736(05)67394-1
|
[57]
|
Nicholls, S.J., Ballantyne, C.M., Barter, P.J., Chapman, J., Erbel, R.M., Libby, P., et al. (2011) Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. The New England Journal of Medicine, 365, 2078-2087.
https://doi.org/10.1056/NEJMoa1110874
|
[58]
|
Giannini, J., Padilla, J., Eaton, R.P., Gonzales, K. and Schade, D.S. (2022) Prevention of Coronary Heart Disease: A Translational Clinical Challenge. World Journal of Cardiovascular Diseases, 12, 11-23. https://doi.org/10.4236/wjcd.2022.121002
|
[59]
|
O’Keefe, J.H., Cordain, L., Harris, W.H., Moe, R.M. and Vogel, R. (2004) Optimal Low-Density Lipoprotein Is 50 to 70 mg/dl: Lower Is Better and Physiologically Normal. Journal of the American College of Cardiology, 43, 2142-2146.
https://doi.org/10.1016/j.jacc.2004.03.046
|
[60]
|
Hu, F.B. and Willett, W.C. (2002) Optimal Diets for Prevention of Coronary Heart Disease. JAMA, 288, 2569-2578. https://doi.org/10.1001/jama.288.20.2569
|
[61]
|
Wiviott, S.D., Cannon, C.P., Morrow, D.A., Ray, K.K., Pfeffer, M.A., Braunwald, E., et al. (2005) Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein with Intensive Statin Therapy—A Prove IT-TIMI 22 Substudy. Journal of the American College of Cardiology, 46, 1411-1416. https://doi.org/10.1016/j.jacc.2005.04.064
|
[62]
|
Sabatine, M.S., Wiviott, S.D., Im, K., Murphy, S.A. and Giugliano, R.P. (2018) Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting with Very Low Levels: A Meta-Analysis. JAMA Cardiology, 3, 823-828. https://doi.org/10.1001/jamacardio.2018.2258
|
[63]
|
Masana, L., Girona, J., Ibarretxe, D., Rodriguez-Calvo, R., Rosales, R. and Carles Vallve, J.-C. (2018) Clinical and Pathophysiological Evidence Supporting the Safety of Extremely Low LDL Levels—The Zero-LDL Hypothesis. Journal of Clinical Lipidology, 12, 292-299. https://doi.org/10.1016/j.jacl.2017.12.018
|
[64]
|
Psaty, B.M. and Lumley, T. (2008) Surrogate End Points and FDA Approval: A Tale of 2 Lipid-Altering Drugs. Journal of the American Medical Association, 299, 1474-1476. https://doi.org/10.1001/jama.299.12.1474
|
[65]
|
Schade, D.S, Cavanaugh, B., Ramo, B. and Eaton, R.P. (2016) The Application of the LDL Principle. World Journal of Cardiovascular Disease, 6, 109-125.
https://doi.org/10.4236/wjcd.2016.65012
|
[66]
|
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., et al. (2016) Interpretation of the Evidence for the Efficacy and Safety of Statin Therapy. The Lancet, 388, 2532-2561. https://doi.org/10.1016/S0140-6736(16)31357-5
|
[67]
|
Joy, T.R., Monjed, A., Zou, G.Y., Hegele, R.A., McDonald, C.G. and Mahon, J.L. (2014) N-of-1 (Single-Patient) Trials for Statin-Related Myalgia. Annals of Internal Medicine, 160, 201-210. https://doi.org/10.7326/M13-1921
|
[68]
|
Schade, D.S., Shey, L. and Eaton, R.P. (2019) Prescribing Statins to Reduce Cardiovascular Disease: 10 Common Misconceptions. The American Journal of Medicine, 132, 897-899. https://doi.org/10.1016/j.amjmed.2019.01.042
|
[69]
|
Jones, P.H., Davidson, M.H., Stein, E.A., Bays, H.E., McKenney, J.M., Miller, E., et al. (2003) Comparison of the Efficacy and Safety of Rosuvastatin versus Atorvastatin, Simvastatin, and Pravastatin across Doses (STELLAR Trial). The American Journal of Cardiology, 92, 152-160. https://doi.org/10.1016/S0002-9149(03)00530-7
|
[70]
|
Brewer, H.B. (2003) Benefit-Risk Assessment of Rosuvastatin 10 to 40 Milligrams. The American Journal of Cardiology, 92, 23K-29K.
https://doi.org/10.1016/S0002-9149(03)00779-3
|
[71]
|
Roberts, W.C. (1997) The Rule of 5 and the Rule of 7 in Lipid-Lowering by Statin Drugs. The American Journal of Cardiology, 80, 106-107.
https://doi.org/10.1016/S0002-9149(97)00298-1
|
[72]
|
Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., et al. (2015) Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. The New England Journal of Medicine, 372, 2387-2397.
https://doi.org/10.1056/NEJMoa1410489
|
[73]
|
Kruit, J.K., Groen, A.K., van Berkel, T.J. and Kuipers, F. (2006) Emerging Roles of the Intestine in Control of Cholesterol Metabolism. World Journal of Gastroenterology, 12, 6429-6439. https://doi.org/10.3748/wjg.v12.i40.6429
|
[74]
|
Connor, W.E., Hodges, R.E. and Bleiler, R.E. (1961) The Serum Lipids in Men Receiving High Cholesterol and Cholesterol-Free Diets. Journal of Clinical Investigation, 40, 894-901. https://doi.org/10.1172/JCI104324
|
[75]
|
Everett, B.M., Smith, R.J. and Hiatt, W.R. (2015) Reducing LDL with PCSK9 Inhibitors—The Clinical Benefit of Lipid Drugs. The New England Journal of Medicine, 373, 1588-1591. https://doi.org/10.1056/NEJMp1508120
|
[76]
|
Thompson, P.D., Clarkson, P. and Karas, R.H. (2003) Statin-Associated Myopathy. JAMA, 289, 1681-1690. https://doi.org/10.1001/jama.289.13.1681
|
[77]
|
Meek, C., Wierzbicki, A.S., Jewkes, C., Twomey, P.J., Crook, M.A., Jones, A., et al. (2012) Daily and Intermittent Rosuvastatin 5 mg Therapy in Statin Intolerant Patients: An Observational Study. Current Medical Research and Opinion, 28, 371-378.
https://doi.org/10.1185/03007995.2012.657302
|
[78]
|
Torimoto, K., Okada, Y., Mori, H., Hajime, M., Tanaka, K., Kurozumi, A., et al. (2013) Efficacy of Combination of Ezetimibe 10 mg and Rosuvastatin 2.5 mg versus Rosuvastatin 5 mg Monotherapy for Hypercholesterolemia in Patients with Type 2 Diabetes. Lipids in Health and Disease, 12, Article No. 137.
https://doi.org/10.1186/1476-511X-12-137
|
[79]
|
Gagné, C., Bays, H.E., Weiss, S.R., Mata, P., Quinto, K., Melino, M., et al. (2002) Efficacy and Safety of Ezetimibe Added to Ongoing Statin Therapy for Treatment of Patients with Primary Hypercholesterolemia. The American Journal of Cardiology, 90, 1084-1091. https://doi.org/10.1016/S0002-9149(02)02774-1
|
[80]
|
FDA Contributors (2012) FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-Lowering Statin Drugs.
https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs
|
[81]
|
Varbo, A. and Nordestgaard, B.G. (2016) Remnant Cholesterol and Triglyceride-Rich Lipoproteins in Atherosclerosis Progression and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 36, 2133-2135.
https://doi.org/10.1161/ATVBAHA.116.308305
|
[82]
|
Scott, R., O’Brien, R., Fulcher, G., Pardy, C., D’Emden, M., et al. (2009) Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals with Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetes Care, 32, 493-498. https://doi.org/10.2337/dc08-1543
|
[83]
|
Cullen, P. (2000) Evidence that Triglycerides are an Independent Coronary Heart Disease Risk Factor. The American Journal of Cardiology, 86, 943-949.
https://doi.org/10.1016/S0002-9149(00)01127-9
|
[84]
|
Campbell, C.L., Smyth, S., Montalescot, G. and Steinhubl, S.R. (2007) Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review. JAMA, 297, 2018-2024. https://doi.org/10.1001/jama.297.18.2018
|
[85]
|
Miedema, M.D., Durprez, D.A., Misialek, J.R., Blaha, M.J., Nasir, K., Silverman, M.G., et al. (2014) The Use of Coronary Artery Calcium Testing to Guide Aspirin Utilization for Primary Prevention: Estimates from the Multi-Ethnic Study of Atherosclerosis. Circulation: Cardiovascular Quality and Outcomes, 7, 453-460.
https://doi.org/10.1161/CIRCOUTCOMES.113.000690
|
[86]
|
Steinhubl, S.R., Bhatt, D.L., Brennan, D.M., Montalescot, G., Hankey, G.J., Eikelboom, J.W., et al. (2009) Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel with Thrombosis and Bleeding. Annals of Internal Medicine, 150, 379-386.
https://doi.org/10.7326/0003-4819-150-6-200903170-00006
|
[87]
|
Patrono, C. and Baigent, C. (2019) Role of Aspirin in Primary Prevention of Cardiovascular Disease. Nature Reviews Cardiology, 16, 675-686.
https://doi.org/10.1038/s41569-019-0225-y
|
[88]
|
Meyer, J., Arps, K., Blumenthal, R.S. and Martin, S.S. (2018) New Data on Aspirin Use in the Era of More Widespread Statin Use. American College of Cardiology, Washington DC.
https://www.acc.org/latest-in-cardiology/articles/2018/09/28/08/08/new-data-on-aspirin-use-in-the-era-of-more-widespread-statin-use
|
[89]
|
McNeil, J.J., Wolfe, R., Woods, R.L., Tonkin, A.M., Donnan, G.A., Nelson, M.R., et al. (2018) Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. The New England Journal of Medicine, 379, 1509-1518.
https://doi.org/10.1056/NEJMoa1805819
|
[90]
|
Gaziano, J.M., Brotons, C., Coppolecchia, R., Cricelli, C., Darius, H., Gorelick, P.B., et al. (2018) Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE): A Randomized, Double-Blind, Placebo-Controlled Trial. The Lancet, 392, 1036-1046.
https://doi.org/10.1016/S0140-6736(18)31924-X
|
[91]
|
Schade, D.S., Burchiel, S. and Eaton, R.P. (2020) A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis. Endocrine Practice, 26, 787-793. https://doi.org/10.4158/EP-2020-0023
|
[92]
|
Nakamura, T., Obata, J.E., Kitta, Y., Takano, H., Kobayashi, T., Fujioka, D., et al. (2008) Rapid Stabilization of Vulnerable Carotid Plaque within 1 Month of Pitavastatin Treatment in Patients with Acute Coronary Syndrome. Journal of Cardiovascular Pharmacology, 51, 365-371. https://doi.org/10.1097/FJC.0b013e318165dcad
|
[93]
|
Grundy, S.M. (1983) Absorption and Metabolism of Dietary Cholesterol. Annual Review of Nutrition, 3, 71-96. https://doi.org/10.1146/annurev.nu.03.070183.000443
|
[94]
|
Schade, D.S., Shey, L. and Eaton, R.P. (2020) Cholesterol Review: A Metabolically Important Molecule. Endocrine Practice, 26, 1514-1523.
https://doi.org/10.4158/EP-2020-0347
|
[95]
|
Sudhop, T., Lütjohann, D., Kodal, A., Igel, M., Tribble, D.L., Shah, S., et al. (2002) Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans. Circulation, 106, 1943-1948. https://doi.org/10.1161/01.CIR.0000034044.95911.DC
|
[96]
|
Eckel, R.H. (2019) Reconsidering the Importance of the Association of Egg Consumption and Dietary Cholesterol with Cardiovascular Disease Risk. JAMA, 321, 1055-1056. https://doi.org/10.1001/jama.2019.1850
|
[97]
|
Netzer, C.T. (2012) The Complete Book of Food Counts. Random House Publishing Group, New York.
|
[98]
|
Myers, J., Prakash, M., Froelicher, V., Do, D., Partington, S. and Atwood, J.E. (2002) Exercise Capacity and Mortality among Men Referred for Exercise Testing. The New England Journal of Medicine, 346, 793-801.
https://doi.org/10.1056/NEJMoa011858
|
[99]
|
Kelley, G.A., Kelley, K.S. and Franklin, B. (2006) Aerobic Exercise and Lipids and Lipoproteins in Patients with Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials. Journal of Cardiopulmonary Rehabilitation, 26, 131-144.
https://doi.org/10.1097/00008483-200605000-00002
|
[100]
|
Welder, G., Zineh, I., Pacanowski, M.A., Troutt, J.S., Cao, G. and Konrad, R.J. (2010) High-Dose Atorvastatin Causes a Rapid Sustained Increase in Human Serum PCSK9 and Disrupts Its Correlation with LDL Cholesterol. Journal of Lipid Research, 51, 2714-2721. https://doi.org/10.1194/jlr.M008144
|
[101]
|
Lambert, G., Sjouke, B., Bhoque, B., Kastelein, J.J. and Hovingh, G.K. (2012) The PCSK9 Decade: Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases. Journal of Lipid Research, 53, 2515-2524.
https://doi.org/10.1194/jlr.R026658
|
[102]
|
Hansson, G.K. (2005) Inflammation, Atherosclerosis, and Coronary Artery Disease. The New England Journal of Medicine, 352, 1685-1695.
https://doi.org/10.1056/NEJMra043430
|
[103]
|
Libby, P. (2002) Inflammation in Atherosclerosis. Nature, 420, 868-874.
https://doi.org/10.1038/nature01323
|
[104]
|
Ross, R. (1999) Atherosclerosis—An Inflammatory Disease. The New England Journal of Medicine, 340, 115-126. https://doi.org/10.1056/NEJM199901143400207
|
[105]
|
Ridker, P.M., Everett, B.M., Thuren, T., MacFadyen, J.G., Chang, W.H., Ballantyne, C., et al. (2017) Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England Journal of Medicine, 377, 1119-1131.
https://doi.org/10.1056/NEJMoa1707914
|
[106]
|
Ridker, P.M. (2001) High-Sensitivity C-Reactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease. Circulation, 103, 1813-1818. https://doi.org/10.1161/01.CIR.103.13.1813
|
[107]
|
Boekholdt, S.M., Arsenault, B.J., Mora, S., Pedersen, T.R., LaRosa, J.C., Nestel, P.J., et al. (2012) Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels with Risk of Cardiovascular Events among Patients Treated with Statins: A Meta-Analysis. JAMA, 307, 1302-1309.
https://doi.org/10.1001/jama.2012.366
|
[108]
|
Gulati, M., Levy, P.D., Muljerkee, D., Amsterdam, E., Bhatt, D.L., Birtcher, K.K., et al. (2021) 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 144, e368-e454. https://doi.org/10.1161/CIR.0000000000001029
|
[109]
|
Schade, D.S., Gonzales, K. and Eaton, R.P. (2021) Stop Stenting; Start Reversing Atherosclerosis. The American Journal of Medicine, 134, 301-303.
https://doi.org/10.1016/j.amjmed.2020.10.009
|
[110]
|
Greenland, P., Knoll, M.D., Stamler, J., Neaton, J.D., Dyer, A.R., Garside, D.B., et al. (2003) Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events. JAMA, 290, 891-897. https://doi.org/10.1001/jama.290.7.891
|
[111]
|
Nasir, K., Rubin, J., Blaha, M.J., Shaw, L.J., Blankstein, R., Rivera, J.J., et al. (2012) Interplay of Coronary Artery Calcification and Traditional Risk Factors for the Prediction of All-Cause Mortality in Asymptomatic Individuals. Circulation: Cardiovascular Imaging, 5, 467-473. https://doi.org/10.1161/CIRCIMAGING.111.964528
|
[112]
|
Cleary, P.A., Orchard, T.J., Genuth, S., Wong, N.D., Detrano, R., Backlund, J.-Y.C., et al. (2006) The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) Study. Diabetes, 55, 3556-3565. https://doi.org/10.2337/db06-0653
|
[113]
|
Martin, S.S., Gosch, K., Kulkarni, K.R., Spertus, J.A., Mathews, R., Ho, P.M., et al. (2013) Modifiable Factors Associated with Failure to Attain Low-Density Lipoprotein Cholesterol Goal at 6 Months after Acute Myocardial Infarction. American Heart Journal, 165, 26-33. https://doi.org/10.1016/j.ahj.2012.10.005
|
[114]
|
Libby, P. (2005) The Forgotten Majority: Unfinished Business in Cardiovascular Risk Reduction. Journal of the American College of Cardiology, 46, 1225-1228.
https://doi.org/10.1016/j.jacc.2005.07.006
|
[115]
|
Libby, P. and Theroux, P. (2005) Pathophysiology of Coronary Artery Disease. Circulation, 111, 3481-3488. https://doi.org/10.1161/CIRCULATIONAHA.105.537878
|
[116]
|
Williamson, J.D., Supiano, M.A., Applegate, W.B., Berlowitz, D.R., Campbell, R.C., Chertow, G.M., et al. (2016) Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥ 75 Years—A Randomized Clinical Trial. JAMA, 315, 2673-2682. https://doi.org/10.1001/jama.2016.7050
|
[117]
|
Howard, B.V., Roman, M.J., Devereux, R.B., Fleg, J.L., Galloway, J.M., Henderson, J.A., et al. (2008) Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes. The SANDS Randomized Trial. Journal of the American Medical Association, 299, 1678-1689.
https://doi.org/10.1001/jama.299.14.1678
|
[118]
|
Libby, P. (2013) Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy. The New England Journal of Medicine, 368, 2004-2013.
https://doi.org/10.1056/NEJMra1216063
|
[119]
|
Budoff, M.J., Lane, K.L., Bakhsheshi, H., Mao, S., Grassman, B.O., Friedman, B.C., et al. (2000) Rates of Progression of Coronary Calcium by Electron Beam Tomography. The American Journal of Cardiology. 86, 8-11.
https://doi.org/10.1016/S0002-9149(00)00820-1
|
[120]
|
Braunwald E (2013) Coronary Plaque Erosion. JACC, 6, 288-289.
https://doi.org/10.1016/j.jcmg.2013.01.003
|
[121]
|
Sukhija, R., Prayaga, S., Marashdeh, M., Bursac, Z., Kakar, P., Bansal, D., et al. (2009) Effect of Statins on Fasting Plasma Glucose in Diabetic and Nondiabetic Patients. Journal of Investigative Medicine, 57, 495-499.
https://doi.org/10.2310/JIM.0b013e318197ec8b
|
[122]
|
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., et al. (2016) Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. The New England Journal of Medicine, 374, 2021-2031.
https://doi.org/10.1056/NEJMoa1600176
|
[123]
|
Ridker, P.M., Danielson, E., Fonseca, F.A.H., Genest, J., Gotto, A.M., Kastelein, J.J.P., et al. (2008) Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. The New England Journal of Medicine, 359, 2195-2207. https://doi.org/10.1056/NEJMoa0807646
|
[124]
|
Ridker, P.M., Pradhan, A., MacFadyen, J.G., Libby, P. and Glynn, R.J. (2012) Cardiovascular Benefits and Diabetes Risks of Statin Therapy in Primary Prevention: An Analysis from the JUPITER Trial. The Lancet, 380, 565-571.
https://doi.org/10.1016/S0140-6736(12)61190-8
|
[125]
|
Brugts, J.J., Yetgin, T., Hoeks, S.E., Gotto, A.M., Shepherd, J., Westendorp, R.G.J., et al. (2009) The Benefits of Statins in People without Established Cardiovascular Disease but with Cardiovascular Risk Factors: Meta-Analysis of Randomized Controlled Trials. BMJ, 338, b2376. https://doi.org/10.1136/bmj.b2376
|
[126]
|
Puri, R., Nicholls, S.J., Shao, M., Kataoka, Y., Uno, K., Kapadia, S.R., et al. (2015) Impact of Statins on Serial Coronary Calcification during Atheroma Progression and Regression. Journal of the American College of Cardiology, 65, 1273-1282.
https://doi.org/10.1016/j.jacc.2015.01.036
|
[127]
|
Benner, J.S., Glynn, R.J., Mogun, H., Neumann, P.J., Weinstein, M.C. and Avorn, J. (2002) Long-Term Persistence in Use of Statin Therapy in Elderly Patients. JAMA, 288, 455-461. https://doi.org/10.1001/jama.288.4.455
|
[128]
|
Ellis, J.J., Erickson, S.R., Stevenson, J.G., Bernstein, S.J., Stiles, R.A. and Fendrick, M. (2004) Suboptimal Statin Adherence and Discontinuation in Primary and Secondary Prevention Population. Should We Target Patients with the Most to Gain. Journal of General Internal Medicine, 19, 638-645.
https://doi.org/10.1111/j.1525-1497.2004.30516.x
|
[129]
|
Mann, D.M., Woodward, M., Muntner, P., Falzon, L. and Kronish, I. (2010) Predictors of Nonadherence to Statins: A Systematic Review and Meta-Analysis. Annals of Pharmacotherapy, 44, 1410-1421. https://doi.org/10.1345/aph.1P150
|
[130]
|
Kalia, N.K., Miller, L.G., Nasir, K., Blumenthal, R.S., Agrawal, N. and Budoff, M.J. (2006) Visualizing Coronary Calcium Is Associated with Improvements in Adherence to Statin Therapy. Atherosclerosis, 185, 394-399.
https://doi.org/10.1016/j.atherosclerosis.2005.06.018
|
[131]
|
Rodriguez, F., Maron, D.J., Knowles, J.W., Virani, S.S., Lin, S. and Heidenreich, P.A. (2019) Association of Statin Adherence with Mortality in Patients with Atherosclerotic Cardiovascular Disease. JAMA Cardiology, 4, 206-213.
https://doi.org/10.1001/jamacardio.2018.4936
|
[132]
|
Olsson, A.G., Pears, J., McKellar, J., Mizan, J. and Raza, A. (2001) Effect of Rosuvastatin on Low-Density Lipoprotein Cholesterol in Patients with Hypercholesterolemia. The American Journal of Cardiology, 88, 504-508.
https://doi.org/10.1016/S0002-9149(01)01727-1
|